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Long-Term Survival After Radical Prostatectomy Compared to Other
Treatments in Older Men With Local/Regional Prostate Cancer
LIQIAN LIU, MD, MS,1 ANN L. COKER, PhD,1 XIANGLIN L. DU, MD, PhD,1*
JANICE N. CORMIER, MD, MPH,2 CHARLES E. FORD, PhD,1 AND SHENYING FANG, MD, MS1
1School of Public Health, University of Texas Health Science Center, Houston, Texas
2Department of Surgical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, Texas
Background: This study aimed to address long-term survival in a large population-based cohort of men with prostate cancer receiving radical
prostatectomy compared to other treatments.
Methods: We studied 5,845 patients diagnosed with local/regional stage prostate cancer at age 65–74 in 1992 with comorbidity score <2, who
were defined as potential candidates for radical prostatectomy and identified from the SEER (Surveillance, Epidemiology and End Results)-
Medicare cohort with median follow-up of 11 years.
Results: Of 5,845 patients, 10-year all-cause survival rates were the highest for patients receiving radical prostatectomy (81.0%; 95% CI: 79.4–
82.4%), followed by radical prostatectomy in combination with radiotherapy (67.6%; 62.0–72.5%), radiotherapy (60.5%; 58.3–62.6%), and were
the lowest for watchful-waiting (50.7%; 47.5–53.8%). A similar pattern was found for 10-year prostate cancer-specific survivals by treatments.
After adjusting for age, ethnicity, region, Gleason Score, comorbidity, median annual household income, hormone therapy and chemotherapy, the
hazard ratio of all-cause mortality was 0.31 (95% CI: 0.25–0.37) for radical prostatectomy and 0.38 (95% CI: 0.28–0.52) for radical
prostatectomy plus radiation therapy compared to those with watchful-waiting.
Conclusions: There was a significant long-term survival benefit in men receiving radical prostatectomy compared to those receiving watchful-
waiting or radiotherapy.
J. Surg. Oncol. 2008;97:583–591.  2008 Wiley-Liss, Inc.
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INTRODUCTION
The efficacy and effectiveness of radical prostatectomy compared to
other primary treatments for prostate cancer, including radiotherapy
and watchful-waiting (observational management), have not been
convincingly demonstrated to date [1–13]. There have been four
randomized trials addressing this issue in patients with localized
prostate cancer [11–14], of which only one demonstrated a survival
advantage of radical prostatectomy over watchful-waiting [14]. Two of
these trials compared radical prostatectomy with external-beam
radiotherapy [12][13] and found a significant reduction in disease
progression associated with radical prostatectomy, one of which also
found that radical prostatectomy was associated with favorable
disease-specific survival but not overall survival [13]. However, the
interpretation of the results from these randomized trials has been
hampered by small sample size [2,11–13], questionable outcome
measures [2][11–13], and incomplete data [12]. In addition, although
randomized controlled trials are the gold standard for determining
efficacy of a therapy, participants in these trials often do not represent
the general population with the disease. Older patients in particular
are under-represented in cancer clinical trials [15–17]. Moreover, it is
important to know whether the efficacy documented under controlled
‘ideal world’ conditions can be translated into ‘real world’ effective-
ness in the community.
To the best of our knowledge, there has been no large population-
based study assessing the effectiveness of radical prostatectomy
compared to other treatments specifically for older men with prostate
cancer. Therefore, our objective was to examine the association
between various prostate cancer treatments and long-term survival in
older men using the nationwide and population-based Surveillance,
Epidemiology, and End Results (SEER) and Medicare linked data.
These data include a large cohort of men diagnosed with prostate
cancer at age 65 or older with up to 11.8 years of follow-up. The data
also provides comprehensive information on patient and tumor
characteristics, such as Gleason score, comorbidities, socioeconomic
status as well as adjuvant therapy. We compared all-cause and prostate
cancer-specific mortality in a cohort of patients who were potential
candidates for radical prostatectomy and other treatment modalities
such as radiation therapy, and observational management. We hypo-
thesized that long-term survival rates would be higher among men with
localized or regional stage prostate cancer who received radical
prostatectomy relative to the other treatments.
PATIENTS AND METHODS
Data Sources
The SEER program of the National Cancer Institute (NCI) includes
population-based cancer registries in the 11 selected geographic areas,
covering approximately 14% of the U.S. population. These areas are:
the metropolitan areas of San Francisco/Oakland, Detroit, Atlanta
and Seattle; Los Angeles county, the San Jose-Monterey area; and the
states of Connecticut, Iowa, New Mexico, Utah and Hawaii. The
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population covered by SEER is comparable to the general U.S.
population with respect to measures of poverty and education [18–20].
The Medicare program covers more than 97% of U.S. population
age 65 years or older for hospital, physician, and other medical services
[19,20]. The linked SEER-Medicare databases were created by
matching cases in SEER against the Medicare master enrollment files.
The SEER-Medicare data, from which this study population was
identified, included cases in the SEER data from 1992 to 1999 and their
Medicare claims through 2002. In this linkage, 93% of persons
aged 65 and older in the SEER were matched to the Medicare
enrollment files. The method of linking these data has been described
elsewhere [19,20]. The Committee for Protection of Human Subjects at
the University of Texas Health Science Center in Houston approved
this study.
Study Population
There were 23,711 prostate cancer cases identified using the
International Classification of Disease (ICD)-9-CM code of
185 reported to SEER in 1992. We studied the cases diagnosed in
1992 only to ensure every case has been followed up for at least
10 years after diagnosis. We excluded patients who did not have
full coverage of both Medicare Part A (inpatient care) and Part B
(outpatient care) or who were members of HMOs because the claims
may be incomplete [21]. A total of 13,933 cases remained and
were initially included in the analysis (Fig. 1). The cohort was further
restricted to patients who were potential candidates for radical
prostatectomy according to the treatment guidelines of National
Cancer Institute (NCI) and National Comprehensive Cancer Network
(NCCN) [22,23]. These include men with localized (tumor confined
within prostate) prostate cancer with at least 10 years of life expectancy
and with no serious comorbidities. Only 5,845 patients diagnosed
with local/regional stage prostate cancer at age 65–74 years with
comorbidity scores of less than 2 were included in our final analysis.
Outcomes
The survival time in months was calculated from the date of
diagnosis to the date of death or to the date of last follow-up (December
31, 2002). Since SEER reported only the month and year of diagnosis,
Journal of Surgical Oncology
Fig. 1. Flowchart of subjects included in the analysis.
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we arbitrarily defined the day of diagnosis as the 15th of the month.
All-cause mortality was defined as death from any cause that was the
underlying cause of death, which was identified by the SEER program
through linking the SEER data with the National Death Index data
from the National Center for Health Statistics. Patients still alive at the
last follow-up were censored. Prostate cancer-specific mortality was
defined as prostate cancer as the underlying cause of death. In this
specific analysis, patients who died of causes other than prostate cancer
or were still alive at the last follow-up were censored.
Treatments
Among the defined cohort of patients, four treatment options were
available, including radical prostatectomy, radiation therapy, radical
prostatectomy in combination with radiation therapy, and watchful-
waiting (or observational management). Radical prostatectomy was
identified if it was indicated in SEER (procedure codes of 40–70) or if
there was a Medicare claim for radical prostatectomy (ICD-9-CM code
of 605, or Common Procedure Terminology (CPT) codes of 55810–
55815 or 55840–55845) [24,25]. Patients were defined as receiving
radiation therapy if it was stated in SEER data or in Medicare with the
following claims codes: [26,27] ICD-9-CM procedure codes of 9221–
9229 for a hospital inpatient or outpatient facility claim of therapeutic
radiology; the CPT codes of 77401–77499 or 77750–77799 for a
physician or outpatient claim of radiotherapy or clinical brachy-
therapy; revenue center codes of 0330 or 0333 for radiotherapy.
Patients were defined as receiving observational management if they
did not receive either prostatectomy or radiation therapy.
Adjuvant hormone therapy was defined if any of the following
Medicare procedure codes were found within 6 months of the diagnosis
of prostate cancer: the Healthcare Common Procedure Coding System
(National Level II) codes of J1950 or J9217–J9219 for leuprolide,
J9202 for goserelin; CPT (National Level I) codes of 54520–54521,
54530 or 54535 for orchiectomy [25,28]. Chemotherapy was
determined if any of the following Medicare procedure codes were
identified within 6 months of the diagnosis of prostate cancer as
described elsewhere [21,28–30]: ICD-9-CM procedure codes of 9925
and V codes of V58.1, V66.2, or V67.2; the procedure codes of 96400–
96549 or J9000–J9999 (except the codes for hormonal therapy above),
Q0083–Q0085; and revenue center codes of 0331, 0332, and
0335 [25,28,31,32].
Comorbidity Index
Patient comorbidity was identified from the Medicare claims
according to diagnoses made or procedures performed in the year
before the diagnosis of prostate cancer. The details of creating a
comorbidity score have been described elsewhere [33]. In brief, the
comorbidity index was based on the Medicare inpatient, outpatient and
physician claim files. For physician and outpatient claims, a patient’s
comorbid diagnoses must appear on at least two different claims that
were more than 30 days apart. Conditions that did not appear on two
different claims were considered ‘‘rule out’’ diagnoses, and were not
counted as comorbidities. We used the SAS macro rule-out programs
available on the NCI website for calculations [28,34]. The program
utilizes claim records and reflects the Deyo adaptation of the Charlson
comorbidity index, with several procedure codes from the Romano
adaptation [35–37].
Other Potential Confounding Variables
Patient age, race/ethnicity, geographic regions, Gleason Score,
tumor stage were available in SEER-Medicare database. We
categorized age into four groups: 65–69, 70–74, 75–79 and 80 or
older; race into white and non-white (blacks, Hispanics and others);
region into Pacific (Los Angeles, San Jose, Seattle, San Francisco and
Hawaii), Mountain (New Mexico and Utah), Central (Iowa), and East
(Connecticut, Atlanta, and Detroit). Gleason Score was classified
into four categories by the SEER: 2–4 (well differentiated), 5–7
(moderately differentiated), 8–10 (poorly differentiated), and
unknown grade. Because local and regional diseases were combined
as a single category in SEER data, we were unable to further stratify
the analysis by local versus regional stage. However, this combined
category may account for the upstaging that would likely occur if all
clinically determined local stage prostate cancers were surgically
staged [38]. We also used the American Joint Committee on Cancer
(AJCC) stage available in SEER to control for residual confounding,
although a large proportion of cases (37%) had missing information on
AJCC stage. We used median annual household income at the zip code
level from the 2000 Census available in the SEER-Medicare linked
files as a proxy indicator of socioeconomic status (SES), which was
categorized into quartiles in the analysis.
Statistical Analysis
Mean survival time and mortality rates per 1,000 person months
were calculated according to treatment modality. Survival rates of
5 and 10 years were calculated and tested by log-rank statistics for
differences between radical prostatectomy and other treatments.
Hazard ratios were calculated for other treatments relative to
watchful-waiting using the Cox proportional hazard model. The
proportional assumption for the Cox proportional hazard model was
assessed graphically and satisfied when the Kaplan–Meier curves for
survival functions by treatments were parallel without intersection
while adjusting for age, race, region, Gleason score, AJCC stage,
comorbidity, median annual household income, hormone therapy and
chemotherapy [39]. The analyses were conducted using STATA
Version 8 (StataCorp LP, College Station, TX, 2005).
RESULTS
Table I presents characteristics of the total population of prostate
cancer cases reported to SEER in 1992 and included in the SEER-
Medicare linked data, as well as the characteristics of patients who
were treated with radical prostatectomy. About 55% of the patients
were younger than 75 years old; a majority (85.5%) were white; most
of the patients (76.7%) had local/regional cancer; 88% of the patients
had a comorbidity score of 0 or 1. Younger men, those with local/
regional disease, fewer comorbidities, and higher median annual
household income were more likely to be treated with radical
prostatectomy (trend test of proportion, P< 0.0001). Patients with
local/regional cancer, age 65–74 and comorbidity score of 0 or
1 represented the greatest proportion of patients who received radical
prostatectomy and were defined as radical prostatectomy candidates as
described in ‘‘Study Population.’’ The subsequent analyses were
restricted to the 5,845 patients who were candidates for radical
prostatectomy according to the clinical guidelines.
Of the 5,845 patients, 2,567 actually received radical prostatectomy,
2,006 received radiation therapy, 302 received radical prostatectomy
plus radiation therapy, and 970 received observational management
(watchful-waiting) (Table II). Generally, younger, white, men with
moderately differentiated tumor, those with low comorbidity score and
with the highest median annual household income were more likely to
receive radical prostatectomy relative to other treatments. In addition,
patients treated with radical prostatectomy were less likely to
receive hormone therapy than those who received watchful-waiting
or radical prostatectomy plus radiation therapy, and also less likely to
receive chemotherapy than the watchful-waiting group (Chi-square
P values 0.05). There was no significant difference between radical
prostatectomy and radical prostatectomy plus radiation therapy groups
Journal of Surgical Oncology
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except in Gleason score, SEER-recoded AJCC stage and receiving
hormone therapy, and also no significant difference in median annual
household income between radical prostatectomy and radiation
therapy groups (Table II).
Table III presents the hazard ratio of mortality for the four treatment
groups. Men who were treated with radical prostatectomy and radical
prostatectomy combined with radiation therapy had significantly
favorable survivals than those who were treated with radiation therapy
alone or watchful-waiting. The mean overall and prostate cancer-
specific survival time was the greatest for those treated with radical
prostatectomy, followed by radical prostatectomy plus radiation
therapy, radiation therapy alone, and was the lowest for watchful-
waiting. Compared to the watchful-waiting group and adjusting for
potential confounders, men who underwent radical prostatectomy were
significantly less likely to die of any causes (aHR¼ 0.31; 95%
CI¼ 0.25, 0.37) or to die of prostate cancer specifically (aHR¼ 0.17;
95% CI¼ 0.10, 0.28). Similarly, men receiving radical prostatectomy
plus radiation therapy were also less likely to die of any cause
(aHR¼ 0.38; 95% CI¼ 0.28, 0.52) or to die of prostate cancer
(aHR¼ 0.23; 95% CI¼ 0.13, 0.48). The magnitude of mortality
reduction was greater for prostate cancer-specific mortality than all-
cause mortality in patients with radical prostatectomy and radical
prostatectomy plus radiation therapy compared to those with watchful-
waiting. Radiation therapy was also associated with a reduced all-
cause and prostate cancer-specific mortality but magnitude was
smaller.
The all-cause and prostate cancer-specific 5- and 10-year survival
rates are presented in Table IV, and the Kaplan–Meier survival
curves are illustrated in Figures 2 and 3. The median follow-up was
132.59 months. As shown in Figure 2, the Kaplan–Meier overall
survivals were markedly different for patients treated with radical
prostatectomy, radical prostatectomy plus radiation therapy, radiation
therapy and watchful-waiting (log-rank test P< 0.0001). Men receiv-
ing radical prostatectomy and radical prostatectomy plus radiation
Journal of Surgical Oncology
TABLE I. Characteristics of Men With Local/Regional Stage Prostate Cancer in 1992 and the Number and
Percentage That Had Radical Prostatectomy
Characteristics
n (%)a of patients
(N¼ 13,933)
n (%)a of patients treated with
radical prostatectomy (N¼ 3,597)
P value, trend of
proportion
Age (years)
65–69 3,445 (24.7) 1,787 (51.9) <0.0001
70–74 4,211 (30.2) 1,426 (33.9)
75–79 3,343 (24.0) 350 (10.5)
80 2,934 (21.1) 34 (1.2)
Race
White 11,908 (85.5) 3,191 (26.8) NA
Non-Whiteb 2,025 (14.5) 406 (20.1)
Comorbidity
0 9,077 (65.2) 2,778 (30.6) <0.0001
1 3,128 (22.5) 626 (20.0)
2 1,098 (7.9) 157 (14.3)
3 630 (4.5) 36 (5.7)
Gleason score
2–4 (well-differentiated) 2,437 (17.5) 395 (16.2) <0.0001
5–7 (moderately differentiated) 6,978 (50.1) 2,357 (33.8)
8–10 (poorly differentiated) 3,056 (21.9) 778 (25.5)
Unknown 1,462 (10.5) 67 (4.6)
SEER-recoded AJCCc stage
I 1,696 (12.2) 376 (22.2) <0.0001
II 1,414 (10.2) 545 (38.5)
III 1,931 (13.7) 1,282 (66.4)
IV 1,550 (11.1) 201 (13.0)
Unknown 7,342 (52.7) 1,193 (16.3)
Extent of disease
Local/regional 10,640 (76.4) 3,379 (31.8) <0.0001
Distant 1,074 (7.7) 16 (1.5)
Unstaged 2,219 (15.9) 202 (9.1)
Regiond
Pacific 5,735 (41.2) 1,764 (30.8) <0.0001
Mountain 1,604 (11.5) 587 (36.6)
Central 1,627 (11.7) 353 (21.7)
East 4,967 (35.7) 893 (18.0)
Median annual household income
1st quartile (<$36951) 3,230 (23.2) 716 (22.2) <0.0001
2nd quartile ($36951–46845) 3,357 (24.1) 825 (24.6)
3rd quartile ($46846–60088) 3,380 (24.3) 950 (28.1)
4th quartile (60089) 3,437 (24.7) 975 (28.4)
Unknown 529 (3.8) 131 (24.8)
aPercentage of cases received radical prostatectomy in the strata (row percentage).
bNon-White: 1,255 blacks (9.0%), 157 Hispanic (1.1%), 613 others (4.4%).
cAmerican Joint Committee on Cancer.
dPacific region includes Los Angeles, San Jose, Seattle, San Francisco and Hawaii; mountain region includes New
Mexico and Utah; central region includes Iowa; east region includes Connecticut, Atlanta, and Detroit.
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therapy had significantly longer survival than men receiving radiation
therapy and watchful-waiting.
The 10-year all-cause survival rates were the highest for patients
treated with radical prostatectomy (81.0%; 95% CI¼ 79.4, 82.4),
followed by patients with radical prostatectomy plus radiation therapy
(67.6%; 95% CI¼ 62.0, 72.5), radiation therapy (60.5; 95% CI¼ 58.3,
62.6), and were the lowest for watchful-waiting (50.7%; 95%
CI¼ 47.5, 53.8). A similar pattern was found for 10-year prostate
cancer-specific survival according to treatment rendered. Five-year all-
cause and prostate cancer-specific survival rates were consistently
higher for radical prostatectomy and radical prostatectomy combined
with radiation therapy relative to the other treatment groups. Patients
receiving radical prostatectomy or radical prostatectomy plus radiation
therapy were not significantly different in 5- and 10-year all-cause and
prostate cancer-specific survival rates (log-rank test P values 0.05).
In addition, as shown in Figure 3, the difference in prostate cancer-
specific survival distributions between radical prostatectomy plus
radiation therapy and radiation therapy was not statistically significant
(log-rank test P¼ 0.70).
DISCUSSION
This study compared the long-term survival among men who
received radical prostatectomy with those who received other
primary treatments such as radiotherapy, watchful-waiting and radical
prostatectomy in combination with radiotherapy. The comparison was
restricted to men with prostate cancer who are candidates for radical
prostatectomy according to the clinical guidelines. We found that men
Journal of Surgical Oncology
TABLE II. Comparison of Potential Risk Factors for Survival Among Various Treatment Modalities
Risk factor
Radical prostatectomy,
n (%) (N¼ 2,567)
Radical prostatectomy and
radiotherapy, n (%) (N¼ 302)
Radiotherapy, n
(%) (N¼ 2,006)
Watchful-waiting,
n (%) (N¼ 970)
Total, n (%)
(N¼ 5,845)
Age (years)
65–69 1,432 (53.0) 164 (6.1) 728 (26.9) 381 (14.1) 2,705
70–74 1,135 (36.2) 138 (4.4) 1,278 (40.7) 589 (18.8) 3,140
P value REF 0.6 <0.0001 <0.0001
Race
White 2,284 (45.0) 267 (5.3) 1,736 (34.2) 787 (15.5) 5,074
Non-White 283 (36.7) 35 (4.5) 270 (35.0) 183 (23.7) 771
P value REF 0.8 0.01 <0.0001
Region
Pacific 1,255 (50.8) 154 (6.2) 684 (27.7) 377 (15.3) 2,470
Mountain 415 (56.5) 38 (5.2) 148 (20.1) 134 (18.2) 735
Central 255 (40.5) 39 (6.2) 240 (38.2) 95 (15.1) 629
East 642 (31.9) 71 (3.5) 934 (46.4) 364 (18.1) 2,011
P value REF 0.2 <0.0001 0.0
Gleason score
2–4 (well differentiated) 286 (26.6) 20 (1.9) 422 (39.2) 349 (32.4) 1,077
5–7 (moderately differentiated) 1,768 (51.8) 153 (4.5) 1,128 (33.1) 362 (10.6) 3,411
8–10 (poorly differentiated) 473 (41.5) 128 (11.2) 365 (32.1) 173 (15.2) 1,139
Unknown 40 (18.4) 1 (0.5) 91 (41.7) 86 (39.5) 218
P value REF <0.0001 <0.0001 <0.0001
AJCC stage
I 301 (36.4) 21 (2.5) 373 (45.1) 133 (16.1) 828
II 460 (55.6) 21 (2.5) 273 (33.0) 73 (8.8) 827
III 914 (67.0) 171 (12.5) 217 (15.9) 63 (4.6) 1,365
IV 112 (34.9) 41 (12.8) 64 (19.9) 104 (32.4) 321
Unkown 780 (31.2) 48 (1.9) 1,079 (43.1) 579 (23.1) 2,504
P value REF <0.0001 <0.0001 <0.0001
Comorbidity
0 2,102 (45.9) 247 (5.4) 1,516 (33.1) 720 (15.7) 4,585
1 465 (36.9) 55 (4.4) 490 (38.9) 250 (19.8) 1,260
P value REF 1.0 <0.0001 <0.0001
Median household income
1st quartile (<$36951) 495 (40.7) 50 (4.1) 412 (33.9) 259 (21.3) 1,216
2nd quartile ($36951–$46845) 584 (42.9) 74 (5.4) 496 (36.5) 206 (15.2) 1,360
3rd quartile ($46846–$60088) 662 (44.6) 81 (5.5) 528 (35.5) 215 (14.5) 1,486
4th quartile (>$60089) 738 (46.9) 88 (5.6) 513 (32.6) 236 (15.0) 1,575
Unknown 88 (42.3) 9 (4.3) 57 (27.4) 54 (26.0) 208
P value REF 0.8 0.1 <0.0001
Hormone therapy
Yes 271 (36.0) 44 (5.8) 170 (22.6) 268 (35.6) 753
No 2,296 (45.1) 258 (5.1) 1,836 (36.1) 702 (13.8) 5,092
P value REF 0.0 0.0 <0.0001
Chemotherapy
Yes 213 (39.4) 27 (5.0) 146 (27.0) 155 (28.7) 541
No 2,354 (44.4) 275 (5.2) 1,860 (35.1) 815 (15.4) 5,304
P value REF 0.7 0.2 <0.0001
P value: Chi-square test for the distribution of the factors among the treatment groups.
REF, reference; race, region and SEER-recoded AJJC Stage are same as in Table I.
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who were treated with radical prostatectomy had significantly longer
survival than those who received other treatments after adjusting for
significant prognostic factors.
Our findings are consistent with those reported by Bill-Axelson
et al. [14] in the randomized clinical trial which demonstrated that
radical prostatectomy was superior to watchful-waiting for localized
prostate cancer in men with mean age of 64.7. With a median of
8.2 years of follow-up in the trial, radical prostatectomy significantly
reduced the prostate cancer-specific (HR¼ 0.56; 95%CI¼ 0.36, 0.88)
and the overall (HR¼ 0.74; 95%CI¼ 0.56, 0.99) mortality. We
observed even stronger positive association between radical prosta-
tectomy and survival compared to watchful-waiting in older men. The
difference in findings may be associated with our longer follow-
up time, larger sample size, and relatively healthy patients with low
comorbidity scores. These may also be reasons that the 10-year overall
and prostate cancer-specific survival rates in the present study are
higher than those reported in the population-based study by Lu-Yao
and Yao [40]. The difference is also likely attributable to the restricted
cohort that included patients potentially eligible for radical prosta-
tectomy and younger patients (65–74 years of age only).
The present research suggests that there may be a benefit over the
10-year follow-up for patients treated with radical prostatectomy over
radiotherapy among those who were candidates for radical prostatect-
omy as defined by age, stage and comorbid conditions. This conclusion
is shared by Paulson [12] and Akakura et al. [13] who found the
advantage of radical prostatectomy in cancer progression and cancer
specific survival rates compared with radiotherapy in their clinical
trials. The difference in risk of dying between radical prostatectomy
and watchful-waiting increases over time in this study. This
observation is consistent with the findings in the study by Holmberg
et al. [5] The same pattern appears between radical prostatectomy and
radiotherapy. These findings may reflect the fact that prostate cancer
is a slowly progressive malignancy, therefore, the effectiveness of
particular treatment modalities will only become evident in studies
with long term follow-up.
There are a number of limitations in this study. First and the most
important concern would be the effect of potential selection bias
because all patients were not randomized into the different treatment
groups but self selected the treatment modality they preferred. The
watchful-waiting group may have included heterogeneous patients. If
the survival outcomes were associated with other factors that led
the patients into different therapy groups rather than the treatment
modalities themselves, the finding could be seriously biased if those
factors were not properly controlled for. For this reason, we carefully
restricted our analysis to the population who were potential candidates
for radical prostatectomy according to the treatment guidelines. For
example, only those patients with tumor confined within prostate, with
at least 10 years of life expectancy and with no serious comorbidities
were selected in order to minimize the selection bias. Furthermore,
there are some differences in the distributions of age, race and cancer
stage in the present study population that composed of 13,933 prostate
cancer cases in the linked SEER-Medicare in 1992 and in the unlinked
(excluded) SEER population that comprised 9,778 prostate cancer
cases in the same year [41]. Compared to the full SEER population
with prostate cancer, the present study population of SEER linked
with Medicare included 3.1% (P¼ 0.0028) fewer cases aged 65–69;
2.4% (P< 0.0001) more white men; 1.5% (P¼ 0.0098) more men
with local/regional stage cancer. While these differences are
statistically significant due to the large numbers with prostate cancer,
these differences on potential selection bias are unlikely to explain
the significant findings for observed association between radical
prostatectomy treatment and survival given that the SEER-Medicare
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TABLE III. Hazard Ratio of Mortality for Patients Receiving Radical Prostatectomy Compared to Patients With
Other Treatments
Treatment modality
Mean survival time
in month (SE)
Mortality ratea
(95% CI) HRb (95% CI)
Overall survival
Radical prostatectomy 127.8 (0.6) 2.0 (1.8, 2.2) 0.31 (0.25, 0.37)
Radical prostatectomy and radiotherapy 120.0 (2.0) 3.3 (2.7, 4.0) 0.38 (0.28, 0.52)
Radiotherapy 112.5 (0.9) 4.2 (4.0, 4.5) 0.68 (0.56, 0.81)
Watchful-waiting 101.2 (1.5) 5.6 (5.2, 6.1) 1.00 (reference)
Prostate cancer-specific survival
Radical prostatectomy 139.7 (0.3) 0.2 (0.1, 0.2) 0.17 (0.10, 0.28)
Radical prostatectomy and radiotherapy 135.2 (1.4) 0.6 (0.4, 0.9) 0.23 (0.13, 0.48)
Radiotherapy 134.6 (0.6) 0.6 (0.5, 0.8) 0.56 (0.37, 0.85)
Watchful-waiting 129.6 (1.1) 1.1 (0.9, 1.4) 1.00 (reference)
CI, confidence interval; HR, hazard ratio; SE, standard error.
aDeaths per 1,000 person-months.
bAdjusted for age, race, region, Gleason score, AJCC stage, comorbidity, median annual household income, hormone
therapy and chemotherapy.
TABLE IV. All Cause and Prostate Cancer-Specific Survival Rates for Patients Receiving Radical Prostatectomy Compared to Patients With Other
Treatments
Treatment
All cause survival % (95% CI) Prostate cancer-specific survival % (95% CI)
5-Year 10-Year 5-Year 10-Year
Radical prostatectomy 93.6 (92.6, 94.5) 81.0 (79.4, 82.4) 98.7 (98.1, 99.1) 98.1 (97.4, 98.6)
Radical prostatectomy
and radiotherapy
91.1 (87.3, 93.8), P¼ 0.7 67.6 (62.0, 72.5), P¼ 0.1 97.3 (94.3, 98.8), P¼ 0.8 94.5 (90.8, 96.8), P¼ 0.1
Radiotherapy 85.0 (83.3, 86.4), P< 0.0001 60.5 (58.3, 62.6), P< 0.0001 95.7 (94.5, 96.7), P< 0.0001 93.8 (92.3, 95.0), P< 0.0001
Watchful-waiting 75.5 (72.6, 73.4), P¼ 0.1 50.7 (47.5, 53.8), P¼ 0.0 91.5 (88.1, 94.0), P¼ 0.0 86.3 (82.1, 89.6), P¼ 0.0
P value: Log-rank test for the difference in survival distribution between radical prostatectomy and other treatment groups after adjusted for age, race, region,
Gleason score, SEER-recoded AJCC stage, comorbidities, median annual household income, hormone therapy and chemotherapy.
CI¼ confidence interval.
588 Liu et al.
Hosted in the Center for Research on Violence Against Women institutional repository with written permission from John Wiley & Sons, Inc.
linked population would have better survival potential (lower stage at
diagnosis and a greater proportion of white race) than the complete
SEER population.
Second, we were unable to control for the level of prostate-
specific antigen (PSA) and physician/hospital characteristics. PSA was
demonstrated to be associated with prostate cancer survival and relapse
by Roehl et al. [42] and Pisansky et al. [43], and physician/hospital
characteristics were suggested to be associated with cancer outcomes
by Begg et al. [44] and Bach et al. [45] Third, misclassification bias
may be present particularly because local and regional stage prostate
cancers were combined into one category by the SEER. However, the
strong survival advantage of radical prostatectomy over the other
treatment modalities in this large, population-based study is unlikely
to be completely explained by variations in PSA or health care
provider characteristics. Fourth, our study was limited to men aged
65–74 years. Therefore, the results might not be generalized to
Journal of Surgical Oncology
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Fig. 2. Overall survival in men with local/regional prostate cancer, by treatment modalities. [Color figure can be viewed in the online issue,
available at www.interscience.wiley.com.]
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Fig. 3. Prostate cancer-specific survival in men with local/regional prostate cancer, by treatment modalities. [Color figure can be viewed in the
online issue, available at www.interscience.wiley.com.]
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younger men with prostate cancer. However, since most of the prostate
cancer cases are older men [46], our findings will be valuable in
generalization to a larger elderly population. Finally, this study did not
examine the morbidity and complications such as impotence and
urinary incontinence, particularly since it was known that radical
prostatectomy is associated with these complications more than other
treatment modalities [47,48]. Therefore, the adverse impact of radical
prostatectomy on health-related quality of life may be a more serious
concern, but that cannot be addressed in our study.
This study has a number of strengths. First, we restricted the
analyses to a cohort of patients who were candidates for radical
prostatectomy based on the clinical guideline, extent of disease and
estimated life expectancy. Such restriction allows a fairer comparison
among the various treatment strategies. In addition, the analyses
controlled for patient comorbidity identified from Medicare claims,
which is a known confounder for treatment choices and survival.
Furthermore, this is a population-based study including incident
prostate cancer cases in 1992 in the SEER regions with up to 11 years
of follow-up, which enables us to observe the long-term outcomes and
the large sample size (5,845 radical prostatectomy candidates)
increases the power to detect differences in survival.
In conclusion, our study demonstrated a significant long-term
survival benefit in men receiving radical prostatectomy compared to
those receiving watchful-waiting or radiotherapy. However, any benefit
of radical prostatectomy on survival must be weighed against the
potential morbidity of surgical treatment, such as impotence and
urinary incontinence. Patients need to be aware of both benefits and
adverse effects of radical prostatectomy compared to other treatments
so that the better and informed treatment decisions can be made. In
addition, further study evaluating the potential survival advantages of
radical prostatectomy among younger men with prostate cancer would
be of interest.
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